EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry

Wanying Xia iD, Yuling Qian, Yangyi Lin, Ruilin Quan iD, Yuanhua Yang, Zhenwen Yang, Hongyan Tian, Shengqing Li, Jieyan Shen, Yingqun Ji, Qing Gu, Huijun Han und 2 weitere

Respirology · 2024

DOI: 10.1111/resp.14700 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Respirology, 2024. Verfasst von Wanying Xia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Vascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking…. Hauptthemen laut MEDLINE: Registries, Off-Label Use, Hypertension, Pulmonary, Antihypertensive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: China Key Research Projects of the 11th National Five-Year Development Plan, China Key Research Projects of the 12th National Five-Year Development Plan, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Off‐label pulmonary arterial hypertension (PAH)‐targeted drugs are commonly prescribed for non‐operated chronic thromboembolic pulmonary hypertension (CTEPH), but their effect on the long‐term prognosis of CTEPH remains unknown. This study investigated the effect of off‐label PAH‐targeted drugs on the long‐term survival of CTEPH patients.

Methods

CTEPH patients were enrolled from a prospective multicentre national registry. Except for licensed riociguat and treprostinil, other PAH‐targeted drugs were off‐label. In the original and propensity score–matched (PSM) samples, five‐year survival was compared in two groups: (a) patients not receiving off‐label PAH‐targeted drugs (control) versus (b) patients receiving off‐label PAH‐targeted drugs (treatment). The latter group was investigated for the effect of started off‐label PAH‐targeted drugs at baselines (initial) or during follow‐up (subsequent).

Results

Of 347 enrolled patients, 212 were treated with off‐label PAH‐targeted drugs initially ( n = 173) or subsequently ( n = 39), and 135 were untreated. The 1‐, 2‐, 3‐ and 5‐year survival of the treatment group was significantly higher than that of the control group (97.1% vs. 89.4%, 92.3% vs. 82.1%, 83.2% vs. 75.1% and 71.1% vs. 55.3%, respectively, log‐rank test, p = 0.005). Initial treatment was correlated with better 5‐year survival after excluding patients with subsequent treatment to reduce the immortal‐time bias (hazard ratio: 0.611; 95% CI: 0.397–0.940; p = 0.025). In PSM samples, patients given initial treatment showed significantly better 5‐year survival than untreated patients (68.9% vs. 49.3%, log‐rank test, p = 0.008).

Conclusion

Off‐label targeted drugs contributed to improved long‐term survival in CTEPH patients receiving pharmacotherapies. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesOff-Label UseHypertension, PulmonaryAntihypertensive AgentsHumansMaleFemaleMiddle AgedProspective StudiesAgedChronic DiseasePulmonary EmbolismSurvival RateTreatment OutcomePyrazolesPyrimidinesPrognosisPropensity Score

Stichwörter der Autor:innen

bosentanchronic thromboembolic pulmonary hypertensionoff‐label targeted drugregistriessildenafil

Substanzen

Antihypertensive AgentsriociguatPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Pulmonary Vascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease…
  • Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Peripheral Vascular Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Respiratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Department of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

ORCID-Profile: Wanying Xia, Ruilin Quan, Jianguo He

Förderung

  • China Key Research Projects of the 11th National Five-Year Development Plan
  • China Key Research Projects of the 12th National Five-Year Development Plan
  • National Key Research and Development Program of China

Zitieren

APA

Xia, W., Qian, Y., Lin, Y., Quan, R., Yang, Y., Yang, Z., Tian, H., Li, S., Shen, J., Ji, Y., Gu, Q., Han, H., Xiong, C., & He, J. (2024). Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry. Respirology. https://doi.org/10.1111/resp.14700

Vancouver

Xia W, Qian Y, Lin Y, Quan R, Yang Y, Yang Z, et al. Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry. Respirology. 2024. doi:10.1111/resp.14700

BibTeX
@article{Xia2024,
  author = {Xia, Wanying and Qian, Yuling and Lin, Yangyi and Quan, Ruilin and Yang, Yuanhua and Yang, Zhenwen and Tian, Hongyan and Li, Shengqing and Shen, Jieyan and Ji, Yingqun and Gu, Qing and Han, Huijun and Xiong, Changming and He, Jianguo},
  title = {Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry},
  journal = {Respirology},
  year = {2024},
  doi = {10.1111/resp.14700}
}
Kostenlos starten →